CLLS - Cellectis SA logo

CLLS

Cellectis SA

Cellectis SA develops gene-editing technologies for immuno-oncology, focusing on allogeneic chimeric antigen receptor T-cell therapies for various cancers, including acute lymphoblastic leukemia and non-Hodgkin's lymphoma.

โš•๏ธ Healthcare NASDAQ Listed 2007 $ USD
$1,000 invested 10 years ago โ†’$107today

Score Overview

1 Year
Score
Net Growth3.28%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth-22.42%
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Score3.7
Net Growth24.23%
Net Trend40%
Net Income Consistencyโ€”
Rev Growth-23.47%
Rev Trend40%
Revenue Consistencyโ€”
10 Years
Score
Net Growth-2.28%
Net Trend40%
Net Income Consistency
Rev Growth32.90%
Rev Trend40%
Revenue Consistency
All Time
Score
Net Growth-13x
Net Trend37%
Net Income Consistency
Rev Growth13x
Rev Trend53%
Revenue Consistency

See the full market ranking โ†’

Cellectis SA fundamental performance

Between 2020 and 2025, revenue declined from $ 73M to $ 72M and net income went from -$ 72M to -$ 67M. Revenue increased in 2 of those 5 years; net income in 2.

Across Cellectis SA's full reported history, from 2007 to 2025, revenue grew from $ 4M to $ 72M and net income went from -$ 4M to -$ 67M. Revenue increased in 53% of the years measured; net income in 37%.

Cellectis SA currently holds a 5-year HDB Score of 3.7 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 2.94โ€”
1 Year2025-08-12
$ 2.6610.53%
5 Years2021-08-12
$ 12.92-77.24%
10 Years2016-08-12
$ 27.59-89.34%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 56M-$ 65M
2025$ 72M-$ 67M$ 208M
2024$ 41M-$ 36M$ 260M
2023$ 755K-$ 101M$ 203M
2022$ 19M-$ 98M$ 97M
2021$ 73M-$ 86M$ 186M
2020$ 73M-$ 72M$ 268M
2019$ 15M-$ 90M$ 360M
2018$ 12M-$ 78M$ 451M
2017$ 25M-$ 99M$ 296M
2016$ 42M-$ 63M$ 290M
2015$ 55M-$ 22M$ 343M
2014$ 26M$ 24.32K$ 136M
2013$ 22M-$ 84M$ 10M
2012$ 27M-$ 29M$ 28M
2011$ 20M-$ 30M$ 54M
2010$ 20M-$ 10M$ 31M
2009$ 17M-$ 5M$ 65M
2008$ 14M$ 185.15K$ 39M
IPO2007$ 4M-$ 4M$ 36M

Explore beyond CLLS

You're looking at Cellectis SA. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies